Isolated limb perfusion: The European experience

Surgical Oncology Clinics of North America

Volumn 10, Issue 4, 2001, Pages 821-832

  Lejeune, F J ^a   Kroon, B B R ^a   Di Filippo, F ^a   Hoekstra, H J ^a   Santinami, M ^a   Lienard D ^a   Eggermont, A M M ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; MELPHALAN; TUMOR NECROSIS FACTOR;

CANCER COMBINATION CHEMOTHERAPY; EUROPE; HUMAN; HYPERTHERMIC THERAPY; LIMB PERFUSION; LIMB TUMOR; MELANOMA; PATIENT MONITORING; REVIEW; SOFT TISSUE SARCOMA; UNITED STATES;

EID: 0035164903     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1055-3207(18)30034-6     Document Type: Review

References (81)

1. Isolated limb perfusion with tumor necrosis factor for malignancies of the limbs
2. Isolated regional perfusion in the treatment of local recurrence, satellitosis and in-transit metastasis of extremity melanoma
3. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity
4. Isolated limb perfusion with melphalan in the treatment of malignant melanoma
5. Neoadjuvant chemotherapy and combined conservative treatment of soft tissue sarcoma in the adult
6. Selective heat sensitivity of cancer cells. Biochemical and clinical studies
7. Heat transfer problems during local perfusion in cancer treatment
8. Hyperthermic antiblastic perfusion in the treatment of stage IIIA-IIIAB melanoma patients. Comparison of two experiences
9. Treatment of malignant melanoma by isolation perfusion technique
10. Hyperthermic isolated regional perfusion of the limb with carboplatin
11. Isolated limb perfusion for local gene delivery: Efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas
12. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion
13. Adenovirus-mediated interleukin-3 beta gene transfer by isolated limb perfusion inhibits growth of limb sarcoma in rats
14. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion
15. The role of hyperthermic perfusion in the treatment of tumors of the extremities
16. Hyperthermic antiblastic perfusion for the treatment of soft tissue limb sarcoma
17. Hyperthermic antiblastic perfusion with TNF alpha and L-PAM in patients with stage II, IIIA and IIIAB limb melanoma
18. Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: Results of a phase I study
19. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience
20. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial
21. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs
22. Tumornecrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability
23. Improved tissue perfusion during pressure regulated hyperthermic regional isolated perfusion. A clinical study
24. High serum levels of TNF-alpha after its administration for isolation perfusion of the limb
25. Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion
26. A prospective randomized study of regional extremity perfusion in patients with malignant melanoma
27. Regional hyperthermic perfusion-therapeutic concept and long term results
28. Is local recurrence of minor importance for metastases in soft tissue sarcoma?
29. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a > 90% response rate and limb preservation
30. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities
31. Low-dose tumour necrosis factor-alpha (TNF-alpha) and melphalan in hyperthermic isolated limb perfusion results from a pilot study performed in the United Kingdom
32. Results of isolated regional perfusion in the treatment of malignant soft tissue tumors of the extremities
33. Continuous leakage monitoring during hyperthermic isolated regional perfusion of the lower limb: Techniques and results
34. Clinical management and current research in isolated limb perfusion for sarcoma and melanoma
35. Results of regional hyperthermic perfusion for primary and recurrent melanomas of the extremities
36. Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma
37. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities
38. Systemic leakage during isolated limb perfusion for melanoma
39. A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities
40. Regional chemotherapy for melanoma. A 35-year experience
41. Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limb
42. Regional perfusion of chemotherapeutic agents by extracorporeal circulation in cancerology. Evaluation of the results
43. Locoregional use of TNF (tumor necrosis factor) in the treatment of malignant melanoma
44. Hyperthermic isolation-perfusion with melphalan, a preliminary appraisal of local and general effects in malignant melanoma
45. Objective regression of unexcised melanoma intransit metastases after hyperthermic isolation perfusion of the limbs with melphalan
46. High dose recombinant tumour necrosis factor (rTNF alpha) administered by isolation perfusion for advanced tumours of the limbs: A model for biochemotherapy of cancer
47. Limb salvage by neoadjuvant isolated perfusion with TNF alpha and melphalan for non-resectable soft tissue sarcoma of the extremities
48. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma
49. In-transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion
50. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study
51. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: A multicentre randomized phase II study
52. A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb
53. Hyperthermic regional perfusion with melphalan and a combination of melphalan and actinomycin D in the treatment of locally metastasized malignant melanomas of the extremities
54. Tumor necrosis factor (TNF)
55. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor
56. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma
57. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: A multicenter study
58. Local heat increases blood flow and oxygen tension in wounds
59. Results of preoperative neoadjuvant chemotherapy and surgery in the management of patients with soft tissue sarcoma
60. Adriamycin in hyperthermic perfusion for advanced limb sarcomas
61. Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas
62. Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion
63. 3 in the disruption of the tumor vasculature induced by TNF and IFN gamma
64. Leakage measurement during selective limb perfusion using a gamma probe
65. Seven years experience with hyperthermic perfusions in extracorporeal circulation for melanoma of the extremities
66. Treatment of recurrent sarcoma of the extremities by isolated limb perfusion using tumor necrosis factor alpha and melphalan
67. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial
68. Systemic toxicity after isolated limb perfusion with melphalan for melanoma
69. Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment
70. Results of hyperthermic perfusion for melanoma of the extremities
71. The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival
72. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects
73. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma
74. Hyperthermic isolated limb perfusion with cisplatin in four patients with sarcomas of soft tissue and bone
75. L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer
76. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors
77. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma
78. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan
79. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions